se of magnesium sulphate as an adjuvant to ropivacaine in pectoral nerve block
Not Applicable
- Conditions
- Health Condition 1: null- Female patients of age between 18 to 65 years, undergoing modified radical mastectomy (MRM) surgery under general anaesthesia.
- Registration Number
- CTRI/2018/07/014747
- Lead Sponsor
- Dr Harmanpreet Kaur Jhand
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
American Society of Anaesthesiologistsâ?? Grade I and II patients.
Patients of age between 18 to 65 years, undergoing modified radical mastectomy (MRM) surgery under general anaesthesia (GA).Patients willing to give informed written consent.
Exclusion Criteria
Patients with any contraindication to regional anesthesia or history of anaphylaxis to local anaesthetics or allergy to the study drugs.ASA-III & ASA-IV patients.
Pregnant or lactating patients.
Patientâ??s refusal for Pectoral nerve block.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate and compare analgesic effect of magnesium sulphate 150mg as an adjuvant to 0.25% ropivacaine versus 0.25% ropivacaine alone in pectoral nerve block in terms of: <br/ ><br>Duration of post-operative analgesia. <br/ ><br>Total analgesic consumption in 24 hours post-operatively.Timepoint: To evaluate and compare analgesic effect of magnesium sulphate 150mg as an adjuvant to 0.25% ropivacaine versus 0.25% ropivacaine alone in pectoral nerve block in terms of: <br/ ><br>Duration of post-operative analgesia. <br/ ><br>Total analgesic consumption in 24 hours post-operatively.
- Secondary Outcome Measures
Name Time Method To record any side effects and patient satisfaction scoreTimepoint: Side effects <br/ ><br>Patient satisfaction score